News|Articles|November 17, 2026

Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLC

Author(s)OncLive Staff
Fact checked by: Ashling Wahner
Listen
0:00 / 0:00

Key Takeaways

  • CHMP’s recommendation positions sintilimab plus pemetrexed/platinum as a potential EU first-line option for nonsquamous NSCLC across PD-L1 strata, pending European Commission approval.
  • ORIENT-11 demonstrated clinically meaningful efficacy, reducing progression/death risk by 52% and improving OS with a 35% relative reduction in mortality versus chemotherapy alone.
SHOW MORE

The CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the marketing authorization of sintilimab (Zybrivo), a PD-1 inhibitor, in combination with pemetrexed (Alimta) and platinum-based chemotherapy for the first-line treatment of adult patients with nonsquamous non–small cell lung cancer (NSCLC).¹

The indication includes locally advanced disease that cannot be managed with curative-intent surgery or chemoradiation, as well as metastatic disease. The European Commission is expected to issue a final decision on marketing authorization for sintilimab in this indication in the coming months.

The recommendation was based on data from the randomized, double-blind phase 3 ORIENT-11 trial (NCT03607539), in which sintilimab in combination with chemotherapy was associated with a 52% lower risk of disease progression or death vs placebo in combination with chemotherapy, with median progression-free survival (PFS) values of 8.9 months vs 5.0 months, respectively. The respective median overall survival (OS) values were 24.2 months vs 16.8 months, translating to a 35% lower risk of death with sintilimab in combination with chemotherapy (HR, 0.65; 95% CI, 0.50-0.85).1,2 The estimated 2-year OS rates were 50% in the sintilimab arm and 32% in the control arm. Additionally, after adjusting for crossover, the OS benefit in the sintilimab arm was more pronounced (HR, 0.52; 95% CI, 0.38-0.69).

The safety profile of sintilimab in combination with chemotherapy in the ORIENT-11 study was in line with the safety profiles of PD-1 inhibitors and the chemotherapy agents used, with no new safety signals observed.1

“The positive CHMP opinion for [sintilimab] marks an important regulatory milestone in our international development and brings us a step closer to serving patients in Europe,” Dr Hui Zhou, chief R&D officer of Oncology at Innovent, stated in a news release. “[Sintilimab] has demonstrated clear clinical benefits in the ORIENT-11 study and, if approved, could provide an additional treatment option for patients in Europe with nonsquamous NSCLC.”

How was the ORIENT-11 trial designed?

The trial included 397 adult patients with nonsquamous NSCLC that was locally advanced, metastatic, or recurrent and had no detectable EGFR or ALK aberrations, irrespective of PD-L1 expression. Patients were randomly assigned 2:1 to receive sintilimab or placebo, each in combination with pemetrexed and platinum-based chemotherapy. The primary end point of the trial was PFS assessed by a blinded independent radiological review committee.

What is the regulatory status of sintilimab in the United States?

On March 24, 2022, the FDA issued a complete response letter (CRL) for the biologics license application seeking the approval of sintilimab plus pemetrexed and platinum-based chemotherapy for the frontline treatment of patients with nonsquamous NSCLC; the CRL was issued after the FDA accepted the submission for review in May 2021.3

The CRL followed a February 10, 2022, meeting of the FDA’s Oncologic Drugs Advisory Committee, which voted 14 to 1 that a new trial representative of the US population was needed. The committee concluded that ORIENT-11 data could not be applied to a US population, noting that the study population was younger, predominantly male, and included more smokers than typical patients in the US. The committee also said that regulatory flexibility did not apply because the agent was not filling an unmet need. The CRL recommended conducting an additional multiregional clinical trial with a noninferiority design and an OS end point.

References

  1. Innovent announces positive CHMP opinion, recommending Zybrivo (sintilimab) for first-line treatment of non-squamous non-small cell lung cancer. News release. Innovent Biologics. November 15, 2026. Accessed November 17, 2026. https://www.prnewswire.com/news-releases/innovent-announces-positive-chmp-opinion-recommending-zybrivo-sintilimab-for-first-line-treatment-of-non-squamous-non-small-cell-lung-cancer-302939658.html
  2. Zhang L, Wang Z, Fang J, et al. Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study. Lung Cancer. 2022;171:56-60. doi:10.1016/j.lungcan.2022.07.013
  3. Rosa K. FDA issues complete response letter to sintilimab/chemo for frontline nonsquamous NSCLC. OncLive. March 24, 2022. Accessed November 17, 2026. https://www.onclive.com/view/fda-issues-complete-response-letter-to-sintilimab-chemo-for-frontline-nonsquamous-nsclc

Related to this article